Page 61 - Read Online

Crisafulli et al. Cancer Drug Resist 2019;2:225-41 I http://dx.doi.org/10.20517/cdr.2018.008 Page 239

Spectrum 2003;95:214-21.
32. Rafnar T, Sigurjonsdottir GR, Stacey SN, Halldorsson G, Sulem P, et al. Association of BRCA2 K3326* with small cell lung cancer and
squamous cell cancer of the skin. J Natl Cancer Inst 2018;110:967-74.
33. Guerra E, Cimadamore A, Simeone P, Vacca G, Lattanzio R, et al. p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast
cancer metastatic spreading. BMC Cancer 2016;16:649.
34. Smith KL, Adank M, Kauff N, Lafaro K, Boyd J, et al. BRCA mutations in women with ductal carcinoma in situ. Clin Cancer Res
2007;13:4306-10.
35. Robson M, Im SA, Senkus E, Xu B, Domchek SM, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA
mutation. N Engl J Med 2017;377:1700.
36. Peeters M, Douillard JY, Van Cutsem E, Siena S, Zhang K, et al. Mutant KRAS codon 12 and 13 alleles in patients with metastatic
colorectal cancer: assessment as prognostic and predictive biomarkers of response to panitumumab. J Clin Oncol 2013;31:759-65.
37. Jia Y, Yun CH, Park E, Ercan D, Manuia M, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective
allosteric inhibitors. Nature 2016;534:129-32.
38. Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, et al. Impact of specific epidermal growthfactor receptor (EGFR) mutations and clinical
characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a
meta-analysis. J Clin Oncol 2015;33:1958-65.
39. Sabapathy K, Lane DP. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others. Nat Rev Clin
Oncol 2018;15:13-30.
40. Zirath H, Frenzel A, Oliynyk G, Segerstrom L, Westermark UK, et al. MYC inhibition induces metabolic changes leading to
accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci U S A 2013;110:10258-63.
41. Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-
driven lymphomas. Proc Natl Acad Sci U S A 2008;105:17961-6.
42. Arango D, Corner GA, Wadler S, Catalano PJ, Augenlicht LH. c-myc/p53 interaction determines sensitivity of human colon carcinoma
cells to 5-fluorouracil in vitro and in vivo. Cancer Res 2001;61:4910-5.
43. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, et al. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic
malignancies harboring PIK3CA mutations. J Clin Oncol 2012;30:777-82.
44. Munoz DM, Cassiani PJ, Li L, Billy E, Korn JM, et al. CRISPR screens provide a comprehensive assessment of cancer vulnerabilities
but generate false-positive hits for highly amplified genomic regions. Cancer Discov 2016;6:900-13.
45. Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, et al. A CRISPR dropout screen identifies genetic vulnerabilities and
therapeutic targets in acute myeloid leukemia. Cell Rep 2016;17:1193-205.
46. Wang T, Yu H, Hughes NW, Liu B, Kendirli A, et al. Gene essentiality profiling reveals gene networks and synthetic lethal interactions
with oncogenic ras. Cell 2017;168:890-903.
47. Shen H, Sun T, Ferrari M. Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther 2012;19:367-73.
48. Day FR, Thompson DJ, Helgason H, Chasman DI, Finucane H, et al. Genomic analyses identify hundreds of variants associated with
age at menarche and support a role for puberty timing in cancer risk. Nat Genet 2017;49:834-41.
49. Dzobo K. Epigenomics-guided drug development: recent advances in solving the cancer treatment “jigsaw puzzle”. OMICS 2019;23:70-
85.
50. Ling A, Gruener RF, Fessler J, Huang RS. More than fishing for a cure: the promises and pitfalls of high throughput cancer cell line
screens. Pharmacol Ther 2018;191:178-89.
51. Rubin AJ, Parker KR, Satpathy AT, Qi Y, Wu B, et al. Coupled single-cell CRISPR screening and epigenomic profiling reveals causal
gene regulatory networks. Cell 2019;176:361-76.
52. Nijman SM. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett 2011;585:1-6.
53. Srivas R, Shen JP, Yang CC, Sun SM, Li J, et al. A network of conserved synthetic lethal interactions for exploration of precision cancer
therapy. Mol Cell 2016;63:514-25.
54. Dixon SJ, Costanzo M, Baryshnikova A, Andrews B, Boone C. Systematic mapping of genetic interaction networks. Annu Rev Genet
2009;43:601-25.
55. Mengwasser KE, Adeyemi RO, Leng Y, Choi MY, Clairmont C, et al. Genetic screens reveal FEN1 and APEX2 as BRCA2 synthetic
lethal targets. Mol Cell 2019;73:885-99.
56. Tharp AP, Maffini MV, Hunt PA, VandeVoort CA, Sonnenschein C, et al. Bisphenol A alters the development of the rhesus monkey
mammary gland. Proc Natl Acad Sci U S A 2012;109:8190-5.
57. Carletti E, Guerra E, Alberti S. The forgotten variables of DNA array hybridization. Trends Biotechnol 2006;24:443-8.
58. Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, et al. Molecular testing guideline for the selection of patients
with lung cancer for treatment with targeted tyrosine kinase inhibitors: American society of clinical oncology endorsement of the
college of American pathologists/international association for the study of lung cancer/association for molecular pathology clinical
practice guideline update. J Clin Oncol 2018;36:911-9.
59. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, et al. Overall survival with durvalumab after chemoradiotherapy in stage III
NSCLC. New England Journal of Medicine 2018;379:2342-50.
60. Ortega VE, Meyers DA. Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine. J
Allergy Clin Immunol 2014;133:16-26.
61. Rabbani B, Nakaoka H, Akhondzadeh S, Tekin M, Mahdieh N. Next generation sequencing: implications in personalized medicine and